Τηλέφωνα επικοινωνίας των υπηρεσιών πρόνοιας για το επίδομα AIDS

Φίλτρο
ΝΟΜΟΣ ΔΗΜΟΣ ΤΗΛΕΦΩΝΟ
ΑΙΤΩΛ/ΝΙΑΣΑΓΡΙΝΙΟΥ2641363400
ΑΙΤΩΛ/ΝΙΑΣΑΜΦΙΛΟΧΙΑΣ2642022266
ΑΙΤΩΛ/ΝΙΑΣΙ.Π ΜΕΣΟΛΟΓΓΙΟΥ2631363432
ΑΙΤΩΛ/ΝΙΑΣΝΑΥΠΑΚΤΙΑΣ2634361218
ΑΡΓΟΛΙΔΑΣΝΑΥΠΛΙΕΩΝ2752029243
ΑΡΚΑΔΙΑΣΤΡΙΠΟΛΗΣ2713600418
ΑΡΤΗΣΑΡΤΑΙΩΝ2681362106
ΑΤΤΙΚΗΣΑΓΙΑΣ ΠΑΡΑΣΚΕΥΗΣ2132100603
ΑΤΤΙΚΗΣΑΘΗΝΑΙΩΝ2105210649
ΑΤΤΙΚΗΣΑΙΓΑΛΕΩ2132044824
ΑΤΤΙΚΗΣΑΧΑΡΝΩΝ2102415380
ΑΤΤΙΚΗΣΕΛΕΥΣΙΝΑΣ2131601403
ΑΤΤΙΚΗΣΚΑΛΛΙΘΕΑΣ2109532717
ΑΤΤΙΚΗΣΝΙΚΑΙΑΣ - ΑΓ.ΙΩΑΝΝΗ ΡΕΝΤΗ2132004813
ΑΤΤΙΚΗΣΠΑΛΛΗΝΗΣ2106604718
ΑΤΤΙΚΗΣΠΕΙΡΑΙΩΣ2131601870
ΑΤΤΙΚΗΣΣΑΛΑΜΙΝΑΣ2132027580
ΑΧΑΙΑΣΠΑΤΡΕΩΝ2610390970
ΒΟΙΩΤΙΑΣΛΕΒΑΔΕΩΝ2261024984
ΓΡΕΒΕΝΩΝΓΡΕΒΕΝΩΝ2462353038
ΔΡΑΜΑΣΔΡΑΜΑΣ2521351123
ΔΩΔΕΚΑΝΗΣΟΥΡΟΔΟΥ2241044741
ΕΒΡΟΥΑΛΕΞΑΝΔΡΟΥΠΟΛΗΣ2551081045
ΕΥΒΟΙΑΣΧΑΛΚΙΔΕΩΝ2221061232
ΕΥΡΥΤΑΝΙΑΣΚΑΡΠΕΝΗΣΙΟΥ2237080238
ΖΑΚΥΝΘΟΥΖΑΚΥΝΘΟΥ2695042544
ΗΛΕΙΑΣΠΥΡΓΟΥ2621360430
ΗΜΑΘΙΑΣΒΕΡΟΙΑΣ2331351918
ΗΡΑΚΛΕΙΟΥΗΡΑΚΛΕΙΟΥ2813409530
ΘΕΣΠΡΩΤΙΑΣΗΓΟΥΜΕΝΙΤΣΑΣ2665099983
ΘΕΣΣΑΛΟΝΙΚΗΣΘΕΣΣΑΛΟΝΙΚΗΣ2313330322
ΙΩΑΝΝΙΝΩΝΙΩΑΝΝΙΤΩΝ2651001041
ΚΑΒΑΛΑΣΚΑΒΑΛΑΣ2513503348
ΚΑΡΔΙΤΣΑΣΚΑΡΔΙΤΣΑΣ2441354719
ΚΑΣΤΟΡΙΑΣΚΑΣΤΟΡΙΑΣ2467350206
ΚΕΡΚΥΡΑΣΚΕΡΚΥΡΑΣ2661035395
ΚΕΦΑΛΛΗΝΙΑΣΚΕΦΑΛΛΟΝΙΑΣ-ΙΘΑΚΗΣ2671022506
ΚΙΛΚΙΣΚΙΛΚΙΣ2341352277
ΚΟΖΑΝΗΣΚΟΖΑΝΗΣ2461029497
ΚΟΡΙΝΘΙΑΣΚΟΡΙΝΘΙΩΝ2741085890
ΚΥΚΛΑΔΩΝΣΥΡΟΥ - ΕΡΜΟΥΠΟΛΗΣ2281079648
ΛΑΚΩΝΙΑΣΣΠΑΡΤΗΣ2731022226
ΛΑΡΙΣΑΣΛΑΡΙΣΣΑΙΩΝ2413549225
ΛΑΣΙΘΙΟΥΑΓΙΟΥ ΝΙΚΟΛΑΟΥ2841340391
ΛΕΣΒΟΥΛΕΣΒΟΥ2251048214
ΛΕΣΒΟΥΛΗΜΝΟΥ2254024011
ΛΕΥΚΑΔΟΣΛΕΥΚΑΔΑΣ2645360615
ΜΑΓΝΗΣΙΑΣΒΟΛΟΥ2421353162
ΜΕΣΣΗΝΙΑΣΚΑΛΑΜΑΤΑΣ2721361858
ΞΑΝΘΗΣΞΑΝΘΗΣ2541350124
ΠΕΛΛΑΣΕΔΕΣΣΑΣ2381351275
ΠΙΕΡΙΑΣΚΑΤΕΡΙΝΗΣ2351351280
ΠΡΕΒΕΖΗΣΠΡΕΒΕΖΑΣ2682089214
ΡΕΘΥΜΝΟΥΡΕΘΥΜΝΗΣ2831341243
ΡΟΔΟΠΗΣΚΟΜΟΤΗΝΗΣ2531022535
ΣΑΜΟΥΣΑΜΟΥ2273080411
ΣΕΡΡΩΝΣΕΡΡΩΝ2321055656
ΤΡΙΚΑΛΩΝΤΡΙΚΚΑΙΩΝ2431063201
ΦΘΙΩΤΙΔΑΣΛΑΜΙΕΩΝ2231350125
ΦΛΩΡΙΝΑΣΦΛΩΡΙΝΑΣ2385044479
ΦΩΚΙΔΑΣΔΕΛΦΩΝ2265350531
ΧΑΛΚΙΔΙΚΗΣΠΟΛΥΓΥΡΟΥ2371351449
ΧΑΝΙΩΝΧΑΝΙΩΝ2821341691
ΧΙΟΥΧΙΟΥ2271350050


Differences between groups of pre-exposure prophylaxis (PrEP) using couples in HIV-negative/unknown relationships

Thu, 11 Apr 2019 00:00:00 GMT-05:00 - John, Steven A.; Robles, Gabriel; Starks, Tyrel J.; Rendina, H. Jonathon
Εισαγωγή: Epidemiology research is limited on the characteristics of HIV pre-exposure prophylaxis (PrEP) using couples. Setting: United States nationwide sample recruited online in 2017.
Μέθοδοι: HIV-negative/unknown gay, bisexual, and other men who have sex with men (GBMSM) with HIV-negative/unknown partners (n=3140) were asked about individual and main partner PrEP uptake. Men were coded into five groups: 1) neither participant nor partner on PrEP, 2) partner only on PrEP, 3) participant only on PrEP, 4) both on PrEP, and 5) unknown partner PrEP use. We examined associations of demographics, relationship factors, condomless anal sex (CAS) with main and causal partners, bacterial sexually transmitted infection (BSTI) diagnoses, and sexual positioning with reported dyadic PrEP use using fully-adjusted multinomial logistic regressions.
Αποτελέσματα: PrEP use was 3.2% for the partner only, 5.7% for the participant only, and 4.9% for both participant and partner; 5.6% reported not knowing their partner’s PrEP use status. Men who reported any CAS with their main partner or any CAS with male casual partners were both more likely to be classified in the dyadic PrEP use group compared to the neither on PrEP group. Compared to monogamous, men in open arrangements were more likely to be classified in each of the three PrEP groups compared to the neither on PrEP group. Six-month BSTI prevalence was 2.8%, 8.1%, 8.3%, 15.6%, and 4.0% for the five groups, respectively.
Συμπεράσματα: PrEP use occurred during times of higher risk behavior engagement, but further efforts are needed to expand PrEP use to more partnered GBMSM. Author to whom correspondence should be addressed; Address: 695 Park Avenue, Room N611, New York, NY 10065; Phone: 212-206-7919; Fax: 212-206-7994; Email: hrendina@hunter.cuny.edu Conflicts of Interest and Source of Funding: Funding: Steven A. John was supported by the Center for AIDS Intervention Research (CAIR) and the National Institute of Mental Health (P30-MH052776, PI: Jeffrey A. Kelly). Gabriel Robles received support from the National Institute on Drug Abuse (R01-DA045613-01S1, PI: Tyrel J. Starks, Awardee: Gabriel Robles). H. Jonathon Rendina was supported in part by a career development award from the National Institute on Drug Abuse (K01-DA039060; PI: H. Jonathon Rendina). Data collection for this paper was supported in part by the Fordham HIV and Drug Abuse Prevention Research Ethics Training Institute (RETI), a training grant sponsored by the National Institute on Drug Abuse (R25-DA031608, PI: Celia B. Fisher). The authors also acknowledge the generous funding provided by the offices of the President, the Provost, and the Dean of Arts & Sciences of Hunter College, CUNY; additional support was also provided by Hunter College’s Center for HIV/AIDS Educational Studies & Training (CHEST). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, Fordham RETI, Medical College of Wisconsin, or Hunter College, CUNY. Conflict of Interest: The authors declare that they have no conflict of interest. Previous meeting where part of these data were presented: International Association of Providers of AIDS Care (IAPAC) Conference, Miami, FL. June 8-10, 2018. - Β© 2019

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

Thu, 11 Apr 2019 00:00:00 GMT-05:00 - Johnson, Margaret; Kumar, Princy; Molina, Jean-Michel; Rizzardini, Giuliano; Cahn, Pedro; Bickel, Markus; Mallolas, Josep; Zhou, Yan; Morais, Cristiana; Kumar, Sushma; Sklar, Peter; Hanna, George J; Hwang, Carey; Greaves, Wayne; for the DRIVE-SHIFT Study Group
Εισαγωγή: Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor (NNRTI) with demonstrated efficacy in treatment-naΓ―ve adults with HIV.
Μέθοδοι: In this open-label, active-controlled, non-inferiority trial, adults with HIV virologically suppressed for ≥6 months on 2 NRTIs plus a boosted protease inhibitor (PI), boosted elvitegravir, or an NNRTI were randomized (2:1) to switch to once-daily, single-tablet doravirine 100mg with lamivudine 300mg and tenofovir disoproxil fumarate 300mg (DOR/3TC/TDF) or to continue their current therapy (Baseline Regimen) for 24 weeks. The primary endpoint was the proportion of participants with HIV RNA <50 copies/mL (FDA Snapshot approach), with the primary comparison between DOR/3TC/TDF at week 48 and Baseline Regimen at week 24, and a secondary comparison between the groups at week 24 (non-inferiority margin, -8%).
Αποτελέσματα: 670 participants (447 DOR/3TC/TDF, 223 Baseline Regimen) were treated and included in the analyses. At week 24, 93.7% on DOR/3TC/TDF vs 94.6% on Baseline Regimen had HIV RNA <50 copies/mL (difference -0.9 [-4.7, 3.0]). At week 48, 90.8% on DOR/3TC/TDF had HIV RNA <50 copies/mL, demonstrating non-inferiority vs Baseline Regimen at week 24 (difference -3.8 [-7.9, 0.3]). In participants on ritonavir-boosted PI at entry, mean reductions in fasting LDL-C and non-HDL-C at week 24 were significantly greater for DOR/3TC/TDF vs Baseline Regimen (p<0.0001). Adverse events occurred in 68.9% on DOR/3TC/TDF and 52.5% on Baseline Regimen by week 24, leading to treatment discontinuation in 2.5% and 0.4%, respectively.
Συμπεράσματα: Switching to once-daily DOR/3TC/TDF is a generally well-tolerated option for maintaining viral suppression in patients considering a change in therapy. Registration: ClinicalTrials.gov NCT02397096 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Corresponding Author: Wayne Greaves, MD, Merck Sharp & Dohme Corp., 126 E. Lincoln Avenue, RY34-A484, Rahway, NJ 07065-0900, (732) 594-3736, 305-7403, wayne.greaves@merck.com Conflicts of Interest and Source of Funding: Funding for this research was provided by Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. MJ has received grants and consulting fees from Gilead and Viiv. PK is on Advisory Boards for ViiV, Janssen, Merck, and Theratechnologies; has received grants from Merck, ViiV, Gilead, and Theratechnologies; and owns stock in Johnson & Johnson, Gilead, Merck, Pfizer, and GSK. J-MM has received grants from Gilead and consulting fees (Advisory Board) from Gilead and MSD. GR has received Advisory board and speaker fees from JanssenCilag, Abbvie, Gilead Science, ViiV, MSD, and Angelini. PC is an Advisory Board member for MSD and ViiV and has received research grants from AbbVie, MSD, and ViiV. MB has no conflicts to declare. JM has received honoraria, speakers’ fees, consultant fees or funds for research from MSD, Roche, Boehringer-Ingelheim, ViiV, Gilead, Janssen, BMS, and Abbvie. YZ, CM, SK, PS, GJH, CH, and WG are current or former employees of MSD. Parts of the data were presented at: IDWeek 2018, San Francisco CA, 04-Oct-2018. - Β© 2019

About us

Στο hivaids.gr, φιλοξενούμε αφιλοκερδώς το "Πρόγραμμα Συνεργασίας" Μονάδων Λοιμώξεων για την ανάπτυξη διαδικτυακής τράπεζας κλινικών παραμέτρων. Το Πρόγραμμα δημιουργήθηκε από έναν γιατρό ειδικό στην HIV λοίμωξη με τη συμμετοχή των Μονάδων: Περισσότερα

% Αναπηρία και HIV

Νέος κανονισμός

Ενιαίος Πίνακας Προσδιορισμού Ποσοστού Αναπηρίας

Ημερολόγιο

@ Διαύγεια

ΔιαύγειαΔι@ύγεια

διαφάνεια στο κράτος

Διαδικτυακές αναρτήσεις διοικητικών αποφάσεων για το HIV/AIDS

Έρευνα

Σας έχει σπάσει ποτέ το προφυλακτικό κατά τη διάρκεια μιας ερωτικής επαφής;
Ναι
Όχι
Δεν χρησιμοποιώ

Επικοινωνία

Newsletter

Ανακοινώσεις

Χρήσιμες πληροφορίες

Τηλεφωνική γραμμή για το HIV/AIDS

210-7222222

Δευτέρα - Παρασκευή
09:00 - 21:00